# Aevice Health **Source:** https://geo.sig.ai/brands/aevice-health **Vertical:** BioTech **Subcategory:** Digital Health **Tier:** Emerging **Website:** aevicehealth.com **Last Updated:** 2026-04-22 ## Summary Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients. ## Company Overview Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists. Founded in Singapore in 2018 and CE-marked in Europe, Aevice Health has conducted clinical studies validating its respiratory AI against expert pulmonologist auscultation. The $30M Series B in 2025 funds U.S. FDA clearance pursuit and commercial expansion across Asia-Pacific and Europe. The technology is particularly relevant for pediatric asthma monitoring where caregiver anxiety and school attendance are major quality-of-life concerns. Respiratory disease affects over 1 billion people globally, with asthma and COPD together accounting for millions of hospitalizations annually — most of which are preventable with earlier intervention. Aevice's continuous monitoring approach shifts respiratory management from episodic clinic visits to proactive remote care, reducing exacerbations and emergency department utilization. ## Frequently Asked Questions ### What does Aevice Health's device do? Aevice Health's wearable chest device continuously monitors breath sounds using AI, detecting wheezing, coughing, and breathing abnormalities to provide early warning of asthma attacks and COPD exacerbations. ### Who uses Aevice Health's technology? Asthma and COPD patients — particularly children and elderly patients at high exacerbation risk — use the AeviceMD wearable, with pulmonologists monitoring data remotely through a clinical dashboard. ### Where is Aevice Health approved? Aevice Health has CE marking for European use and is pursuing U.S. FDA clearance, with clinical deployments across Asia-Pacific and Europe. ### What is Aevice Health's AeviceRx device? AeviceRx is a wearable respiratory monitoring device that attaches to the chest and continuously listens to lung sounds, using AI to detect wheezing, crackles, and other abnormal sounds associated with asthma, COPD, and respiratory infections. Unlike conventional peak flow meters that require patient effort at specific intervals, AeviceRx provides continuous, passive monitoring during normal activity and sleep. ### What is Aevice Health's regulatory status? Aevice Health has received regulatory clearance in Singapore (HSA) and is pursuing CE marking for the European Union and FDA clearance for the US market. Singapore served as the initial validation market given the country's robust MedTech regulatory pathway and high smartphone penetration that enables connected health device deployment. The regulatory strategy sequences approval in major markets based on clinical evidence generated in Singapore trials. ### How much has Aevice Health raised and who are its investors? Aevice Health has raised early-stage funding from Singapore-based health tech investors and regional venture funds. The company participates in Singapore's National Medical Research Council grant programs and has received support from Singapore's health innovation ecosystem including Changi General Hospital collaborations for clinical validation. ### How does Aevice Health's AI interpret lung sounds? Aevice AI's algorithm is trained on thousands of clinically labeled respiratory sound recordings, learning to distinguish normal breathing from pathological patterns (wheezing in asthma, crackles in pneumonia or COPD, stridor). The model runs on-device for real-time detection and alerts, with raw audio data optionally transmitted to the cloud for more detailed analysis. Clinician-validated performance is benchmarked against expert pulmonologist auscultation in clinical studies. ### What is the target patient population for Aevice Health? Aevice Health targets chronic respiratory disease patients — the 300+ million people globally with asthma and the 200+ million with COPD — who require ongoing monitoring to detect exacerbations before hospitalization. Early exacerbation detection enables medication adjustment that prevents emergency department visits, which cost $1,500-3,000 per event. Payers and health systems see strong health-economic justification for continuous monitoring devices that demonstrably reduce hospitalization rates. ## Tags healthtech, iot, ai-powered, startup, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*